US Patent Issued to ImmunityBio on Sept. 2 for "Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)" (California Inventors)

ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,403,178, issued on Sept. 2, was assigned to ImmunityBio Inc. (Culver City, Calif.).

"Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)" was invented by Patrick Soon-Shiong (Culver City, Calif.), Hans G Klingemann (Culver City, Calif.), Laurent H Boissel (Culver City, Calif.), Himani Chinnapen (Culver City, Calif.) and Abhijit Dandapat (Culver City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells...